| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e28dc400a1338edf7c98614411f820bb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate |
2003-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f87e9a56ea1c5a21cc365ba0d6c804f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c642a7d5cc3b35ccec24e8fea40389f |
| publicationDate |
2004-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2496005-A1 |
| titleOfInvention |
Use of botulinum toxin for the treatment of fine wrinkles and pore size |
| abstract |
Methods of using clostridial toxins and other biological agents to control holocrine gland dysfunction in humans is provided. In preferred embodiments the methods provide beneficial effects in humans. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8202522-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8153139-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10980865-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8034357-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11191819-B2 |
| priorityDate |
2002-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |